Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275300 · ClinicalTrials.gov registry record · NA
Biosynthesis of PGD2 in Vivo
A NA study of Hyperlipidemia, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01275300: Completed NA study of Hyperlipidemia, sponsored by University of Pennsylvania.
NCT01275300 is a NA study of Hyperlipidemia that has completed, run by University of Pennsylvania. The registered enrollment target is 9 participants, below the 408-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01275300, a NA study of Hyperlipidemia, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin. Phase I: Subjects were assigned to either placebo or aspirin groups. They were given 5 days of 81 mg aspirin or placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. The same subjects came back for cross-over study and were assigned to a different group. There was a 2-week washout period between each treatment. Urine was collected sequentially for analysis Phase II: The same study subjects come back for an open label one week study. They were given 5 days of taking 81 mg Aspirin, taken once daily, followed by a single dose of 600 mg Niacin on day 6. Urine was collected sequentially for analysis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Niacin
- DRUG Aspirin
Study Locations (1)
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275300
The ClinicalTrials.gov registry entry for NCT01275300 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01275300 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01275300 about?
NCT01275300 is a clinical study titled "Biosynthesis of PGD2 in Vivo". The investigator would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin. Phase I: Subjects were assigned to either placebo or aspirin groups. They were given 5 days of 81 mg aspirin or placebo. On day 5, they were given a single dose of ni...
What is the current status of trial NCT01275300?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2007-07. Estimated completion is 2012-01.
What conditions does trial NCT01275300 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT01275300?
The interventions under investigation include: Placebo (DRUG), Niacin (DRUG), Aspirin (DRUG).
Who is sponsoring clinical trial NCT01275300?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01275300 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
RECRUITING · NA
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management
COMPLETED · NA
-
The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
COMPLETED · NA
-
Eating Peanuts for Health
COMPLETED · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.